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Abstract
IL-2 is the primary growth factor for promoting survival and proliferation of activated T cells that occurs following
engagement of the Janus Kinase (JAK)1–3/and Signal Transducer and Activator of Transcription (STAT) 5 signaling pathway.
STAT5 has two isoforms: STAT5A and STAT5B (commonly referred to as STAT5) which, in T cells, play redundant roles
transcribing cell cycle and survival genes. As such, inhibition of STAT5 by a variety of mechanisms can rapidly induce
apoptosis in certain lymphoid tumor cells, suggesting that it and its target genes represent therapeutic targets to control
certain lymphoid diseases. To search for these molecules we aligned IL-2 regulated genes detected by Affymetrix gene
expression microarrays with the STAT5 cistrome identified by chip-on-ChIP analysis in an IL-2-dependent human leukemia
cell line, Kit225. Select overlapping genes were then validated using qRT2PCR medium-throughput arrays in human PHA-
activated PBMCs. Of 19 putative genes, one key regulator of T cell receptor signaling, PDE4B, was identified as a novel
target, which was readily up-regulated at the protein level (3 h) in IL-2 stimulated, activated human PBMCs. Surprisingly,
only purified CD8+ primary T-cells expressed PDE4B, but not CD4+ cells. Moreover, PDE4B was found to be highly expressed
in CD4+ lymphoid cancer cells, which suggests that it may represent a physiological role unique to the CD8+ and lymphoid
cancer cells and thus might represent a target for pharmaceutical intervention for certain lymphoid diseases.
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Introduction
The mammalian Signal Transducer and Activator of Tran-
scription (STAT) family is composed of 7 members (1–4, 5a, 5b
and 6). STAT molecules exert critical roles in cell proliferation,
differentiation and survival (reviewed in [1]). Originally, STATs
were believed to be latent factors residing in the cytosol and
only activated when cytokines bind to their cognate receptor
after activation of Janus tyrosine kinases (JAK). Indeed the
central model suggests that JAKs phosphorylate tyrosine
residues on the receptor serving as docking sites for SH2
domain-containing signaling molecules such as STATs. Follow-
ing docking via phosphotyrosine-SH2 interactions, STATs
themselves become tyrosine phosphorylated by JAKs, disengage
from the receptor and form dimers via reciprocal phosphotyr-
osine-SH2 domain interactions. The STAT dimer is then
translocated to the nucleus to initiate gene transcription [2–3].
However we now know that STATS can dimerize and form
tetramers in the absence of tyrosine phosphorylation and be
nuclear localized to control gene regulation in many unique
ways that are less understood [4–5].
What is clear is that STATs 1, 3, 5A and 5B are widely utilized
by various cytokines and are important for the regulation of
cellular growth, proliferation and death, while STATs 2, 4 and 6
promote viral defense and Th1 versus Th2 differentiation,
respectively. Moreover, STAT3 and STAT5 have been found to
be closely related and relevant to tumorigenesis (reviewed in [1]).
Indeed, constitutively tyrosine phosphorylated forms of STAT5
are readily observed in a variety of cancerous cells and tissues of
distinct origins as a result of chromosomal translocation,
deregulated tyrosine kinases and viral transformation (reviewed
in [1]).
The physiological role of STAT5A and B is largely derived from
in vivo studies of STAT5A and B knockout animals. From these
studies it appears clear that STAT5A is mainly involved in
mammary gland development [6] and STAT5B is responsible for
regulating growth via growth hormone signaling [7]. In T
lymphocytes, however, they have compensatory functions: studies
from STAT5A/B double deficient mice showed that they have
redundant roles in mediating cell cycle progression of activated T
cells [8,9]. In addition, studies employing STAT5A/B null mice
indicate that these molecules are important for lymphoid organ
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development as a deficiency in these proteins can result in severe
combined immunodeficiency phenotype [10]. Moreover, STAT5
appears to act as a critical survival factor for T-cells, since
constitutively active (i.e. tyrosine phosphorylated) STAT5 is often
present in lymphoid and leukemic cancer cells among other types
of tumors as compared to normal, non-transformed cells (reviewed
in [1]). Furthermore, blocking STAT5 expression in human
peripheral blood mononuclear cells as well as lymphoid and
leukemic cancer cells severely compromise cell viability and induce
apoptotic cell death [11]. Evidence from many groups suggests
that STAT3 plays a similar oncogenic role to STAT5 and
dependent upon the cell type, one may be more dominant [12].
New findings for this family of proteins also suggest that their cell
survival promoting characteristics when un-phosphorylated can
play a gene regulatory role as well [4]. These data help provide
intriguing new models that suggest that pharmacological uncou-
pling of activated as well as un-activated STAT5 may be required
to disrupt their target genes to induce cancer cell death. Thus,
identifying cell survival and tumor relevant STAT5 target genes is
an important goal for the development of novel anti-cancer
therapies.
One method that has proven successful in identifying novel
target genes is chromatin immunoprecipitation which can reveal
direct transcription factor- DNA interactions [13] and allows for
the identification of unknown transcription factor binding sites in
novel target genes by generating a genome-wide library that can
be (i) sequenced and located in the human genome, or (ii)
hybridized to microarrays representing non-coding regions of the
genome. Genome-wide mapping of cytokine induced STAT5
target genes have been performed and published in various cell
types (T-, pre-B-, human NK-like tumor and breast cancer cells)
using ChIP-clone or ChIP-Seq technologies [4] [14–18]. In
particular, mapping IL-2 inducible STAT5 binding events and
transcriptional changes in primary T cells using ChIP-Seq, gene
expression microarrays, or RNA-Seq technology have been
performed and published for both mouse [5,16,19,20] and human
[16,19] models. These important studies primarily focused on the
role of STAT5 in T helper cell differentiation and physiological
immune responses.
The present work sought to identify key cell survival and tumor
relevant STAT5 target genes in IL-2 dependent human leukemia
cells using gene expression and promoter microarray studies. The
results of which were aligned and a select pool of candidate targets
were then validated in normal human activated PBMCs.
Phosphodiesterase (PDE) 4B, a regulator of cyclic AMP signaling
in T cells was shown to be IL-2 regulated in primed human
PBMCs and CD8+ purified T cells. Interestingly this molecule was
strongly over-expressed in lymphoid tumor but not primed
primary CD4+ T cells.
Results and Discussion
A Genome-wide Approach to Identify STAT5 Specific IL-
2-mediated Genes
STAT5 is a potent regulator of T cell survival as its depletion
results in massive cell death of activated T and lymphoid tumor
cells [11–12]. To date, genome-wide studies have been utilized to
identify and locate IL-2 regulated STAT5 binding events and
target genes in normal mouse [5,16,19,20] and human T cells
[16,19] reviewed in [21]. However, in the present study we sought
to identify genome-wide IL-2 mediated STAT5 gene targets from
lymphoid tumor cells (Figure S1). To systematically map STAT5
binding sites on the genomic scale that we define as the STAT5
cistrome [22] and IL-2 mediated gene expression changes we
employed microarrays. For these studies we first determined the
STAT5 cistrome using chip-on-ChIP in IL-2 dependent Kit225
cells that were either left un-stimulated or stimulated with IL-2 for
30 minutes, followed by subsequent gene expression analysis to
detect IL-2 mediated mRNA changes at 3 hours. The resultant
data pools were then statistically analyzed and aligned and a select
set of genes that harbored STAT5 binding sites within their
promoter regions were validated using medium throughput
qRT2PCR arrays.
Generating a Library of IL-2 Regulated STAT5 Binding
Sites
First, three biological replicates of ChIP were performed
utilizing a mixture of antibodies directed toward the C-terminal
of STAT5A and STAT5B in Kit225 cells stimulated with IL-2 for
30 min. The assay was validated by measuring the IL-2 induced
enrichment of the IL2RA enhancer [23] element named Positive
Regulatory Region (PRR) III (Figure 1A) via STAT5 antibodies as
compared to the control serum. Next, the captured DNA was
amplified as described in the Materials and Methods using
a random amplification protocol. To confirm that the libraries
remained enriched for the positive control PRR III element post-
amplification, PRR III was measured using qPCR (Figure 1B)
from all the replicate experiments. Next, microarray analysis using
Affymetrix GeneChip Human Promoter 1.0R arrays was carried
out employing input genomic DNA (as a control) and the IL-2
stimulated samples in three biological replicates as described
above. The resulting ‘‘.cel files’’ were then analyzed using MAT
(Model-based Analysis of Tiling array, [24]) that yielded ‘‘.bed
files’’ with the chromosomal coordinates of all ChIP-regions
including p-values, MAT scores (to allow enrichment in different
regions of different length to be compared directly), FDR (false
discovery rate) calculations and repeat flags. Repetitive and
segmental duplication elements were removed and the remaining
1581 hits were mapped with CEAS (Cis-regulatory Element
Annotation System) [25] within 300 kb of annotated genomic
regions. As shown in Figure 2A only about 17% of candidate genes
lie within nearby promoters, while about 25% and 42% are
located in enhancers and introns, respectively. These findings are
in good agreement with others’ data indicating that the majority of
the TF binding sites are found in intronic and intergenic regions
[26]. To compare our results with previously published ChIP-Seq
data sets, STAT5A and STAT5B binding sites derived from
primary human CD4+ T-cells were re-analyzed (GSE27158, [16]
using a ChIP-Seq analysis pipeline by Barta et al, [27]) and the
resultant peaks subjected to CEAS analysis. The resulting
outcomes for STAT5A and STAT5B sites distribution were as
follows: promoter-bound 21% and 19%, intronic 34% and 35%,
enhancer-bound 38% and 39%, respectively, indicating that the
genomic STAT5 binding pattern from the current chip-on-ChIP
data sets closely match the ChIP-Seq results by Liao and
colleagues [16]. Interestingly only about 20% of the STAT5
binding sites were confined to promoters. Next, the enrichment of
TF binding motives were also analyzed based on the CEAS
assigned fold change value which represents significantly enriched
motives with .2 fold-change within the ChIP regions over the
whole genome. Figure 2B upper table and panel shows that the TF
motives with the highest fold changes include the classical STAT
binding motives TTCNNNGAA in various forms. The Interferon
Sensitive Response Element (ISRE) was also significantly enriched
which suggests that in certain cells STAT5 can also possibly bind
to these motifs: either directly or by the assistance of another TF
that binds ISRE. Figure 2B lower table and panel represent the
most significantly enriched TF binding sites. Intriguingly these are
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TTC STAT half-sites. Perhaps in these types of cells STAT5 can
bind half-sites directly or indirectly, suggesting an abnormal
regulation as this type of DNA binding has not been observed
in vitro [28].
Identifying IL-2 Regulated Genes in Kit225 Cells Using
Gene Expression Analysis
In order to identify IL-2 mediated genes in Kit225 cells, cells
depleted of IL-2 were treated with IL-2 or control vehicle for 3
hours and subjected to gene expression microarray analysis in two
biological replicates. From this analysis, 469 genes changed greater
than 2-fold, with 129 down- and 340 up-regulated genes including
several IL-2 mediated targets such as CISH, SOCS1, OSM, PIM-
1, BCL6 and BCL2. This gene list was analyzed with the Ingenuity
Pathway Analysis web-based software which further confirmed
STAT5A and STAT5B activation status following IL-2 treatment
(Figure S2) and identified cellular networks relevant to immune
function including Cellular Development & Cell Cycle, Hemato-
Figure 1. IL-2 mediated enrichment of the STAT5 binding site in the IL-2RA enhancer (A) before and (B) after amplification. (A) Kit225
IL-2-dependent human leukemia cells were made quiescent and then stimulated with medium (2) or IL-2 (+) for 30 min at 37uC, fixed with 1%
formaldehyde for 10 min at room temperature and then chromatin immunoprecipitated with antibodies to C-terminal STAT5A/B mix or control IgG.
The eluted DNA was amplified with primers corresponding to the human IL2RA PRR III. Representative data from three independent experiments are
shown. Input material represents 5% of immunoprecipitated chromatin. Beads control represents samples in which immunoprecipitation was
performed without any antibodies but otherwise was handled identically. (B) Cells were treated as described above and then for the microarray
experiments the ChIP-ed DNA was randomly amplified following ligation of linkers as described in the Materials and Methods section from three
independent experiments. The amplified DNA was then used as template in qPCR reactions to measure the enrichment of the IL2RA PRR III.
doi:10.1371/journal.pone.0057326.g001
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logical System Development & Function, Reproductive System
Development & Function as well as Cellular Movement, Growth
& Proliferation significantly overrepresented (Figure S3).
Identifying IL-2 Regulated Genes of the STAT5 Cistrome
Our aim was to discover a pool of IL-2 responsive genes that
contain STAT5 regulatory sites. Therefore, we created intersect
of the STAT5 cistrome and the IL-2 responsive genes using the
UCSC Table Browser. First, the Affymetrix IDs of the gene
expression pool were converted to genomic locations (.bed files)
that were then aligned with the chip-on-ChIP results. These
pools were visualized on the genomic scale using the ‘‘.bed files’’
and the Integrative Genomics Viewer (IGV, Figure 3). From the
intersect pool comprised of 106 genes, a list of 57 genes that
Figure 2. Cis-Regulatory Element Annotation System (CEAS) analysis of STAT5 binding elements. (A) Genome-wide distribution of
STAT5 binding sites (percent of total number of sites). The chip-on-ChIP identified elements that fell within 300 kb from coding regions were
analyzed based on their distance from nearest genes using CEAS. The pie chart represents ‘‘%’’ distribution. (B) Enriched transcription factor
binding motifs with highest fold-change (upper panel) and highest significance (lower panel). Enriched TF binding sites and their
matrices within the chip-on-ChIP identified, CEAS analyzed regulatory elements are shown.
doi:10.1371/journal.pone.0057326.g002
Determining the STAT5 Cistrome in Leukemia Cells
PLOS ONE | www.plosone.org 4 February 2013 | Volume 8 | Issue 2 | e57326
contained the STAT5 regulatory sites within their proximal
promoter (30 genes), immediate downstream segments of the
gene (7 genes), enhancer (14 genes) or first exon (6 genes) were
chosen for validation in human primed PBMCs (Figure 3 and
Table S1.) at the mRNA level using medium throughput
qRT2PCR gene expression arrays (described in the Materials
and Methods and statistically significant results (p-value ,0.05)
shown in Table 1). The known IL-2 target genes (indicated by
asterisks in Table 1) BCL2, BCL6, CDK6 and IL2RA were
identified as IL-2 inducible genes with STAT5 binding sites.
Other known IL-2 target genes such as CISH, IFNG and
FOXP3 were also identified by GEA and therefore were
included as positive controls on the arrays. Although these genes
are known to be regulated by STAT5, in Kit225 cells their
STAT5 binding sites were not identified by the chip-on-ChIP
analysis, for which we cannot rule out a cell type specific effect.
To clarify these findings, IGV was used to visualize the genomic
locations of known (SOCS2, SOCS3, IL2RA, CISH, BCL2,
BCL6 and CDK6 (Figure 4A) underlined are those identified in
our screen) and 18 unknown IL-2/STAT5 target genes
(Figure 4B). Among these for instance, CD69 (up 2.3-fold) has
been shown to influence Th17 differentiation, which is a known
STAT5-dependent process [29]. CDKN2C, otherwise called as
p18(INK)4c, is a known inhibitor of G1 cell cycle initiation,
which here is down-regulated about 2-fold by IL-2. Lymphocyte
Cytosolic Protein (LCP) 2 (1.7-fold up) is a target for Zap70
kinase in T lymphocytes and its deficiency is known to induce
an absence of double-positive CD4+CD8+ thymocytes and of
peripheral T cells [30]. RAFTLIN (raft-linking protein) was also
shown to influence T-cell mediated immune responses and
Th17 differentiation [31]. STK17B is a serine kinase also
known as DRAK (DAP kinase-related apoptosis-inducing kinase)
2 which is known to mediate apoptosis induced by IL-2 and
regulate T cell receptor sensitivity in developing thymocytes
[32–33]. Phosphodiesterase (PDE) 4 B is a type 4 PDE (up ,2-
fold) that regulates TCR signaling by tempering the negative
effect of cAMP [34] and in CD4+ human T cells decreased
PDE4B expression leads to reduced IL-2 production upon anti-
CD3/CD28 co-stimulation [35]. The chip-on-ChIP identified
STAT5 binding site within the PDE4B is shown in Figure 4B,
visualized by the IGV. Intriguingly, IL-2 increased the level of
PDE4B, which contains several intronic STAT5 binding sites,
based on murine T cell studies [5].
STAT5 Occupies a Putative IL-2 Responsive GAS Site
within the PDE4B Gene in vivo in Human PBMCs
To confirm that STAT5 is able to bind a putative GAS site
within the PDE4B gene (located on chromosome 1, hg18
positions 66567898–66573077) in an IL-2 inducible manner, we
performed ChIP experiments in quiescent human PBMCs left
untreated (2) or treated with IL-2 for 30 min (+) isolated from
three independent donors. As a result we observed that STAT5
bound PDE4B in an IL-2 dependent and significant manner
(p,0.05) with an approximately 1.7-fold increase as compared
to the untreated cells (Figure 5A). The IL2RA PRR III was
used as a positive control (Figure 5B). Interestingly, the PDE4B
gene contained both STAT5A and STAT5B IL-2 responsive
binding sites investigated within primary human T cells [16]
that overlapped with our chip-on-ChIP region. Moreover, the
increased STAT5 DNA binding activity following IL-2 treat-
ment correlated well with the observed 2-fold increase in
mRNA levels (Table 1).
Short Term IL-2 Treatment (3 h) Induces PDE4B Protein
Expression in PHA-activated Human PBMCs and CD8+
but not CD4+ Cells
To further validate that PDE4B is regulated by IL-2, we also
examined protein level changes in naı¨ve (N), PHA-activated (A),
quiescent (Q) and IL-2 stimulated human PBMCs at 3 h (+) in
two independent donors (Figure 6A). The level of PDE4B
protein increased approximately 2-fold (Figure S4, densitometry
analysis), which correlates with the ,1.7-fold increase in DNA
binding activity of STAT5 and 2-fold increase in mRNA levels
(Figure 5A and Table 1, respectively). Primary human CD4+ or
CD8+ T-cells were also tested (Figure 6B). YT NK-like cells
served as positive control and ß-actin as a loading control. Both
PHA-activation (72 h) and short term IL-2 treatment induced
PDE4B protein expression in PBMCs and CD8+ but not CD4+
T-cells. Based on this data it is interesting to speculate that
PDE4B might be the first ‘‘line of defense’’ in PBMCs and
CD8+ T-cells against the elevated cAMP signaling that occurs
with T-cell stimulation [36]. It is known that another type 4
isoform, PDE4D is also expressed in CD4+ T-cells [35], which
leads us to speculate a possible model where there is constant
tempering of cAMP induced pathways as compared to CD8+
cells. Another possibility might be that the delayed up-regulation
of PDE4B in CD4+ cells is to down-regulate cAMP in these
cells at a distal point of time. Testing of CD4+ vs CD8+ cells
was performed from a single donor and we believe provides
new opportunities to investigate the possible role of PDE4B in
these types of T cell subsets.
PDE4B is Expressed in CD4+ Lymphoid Tumor Cell Lines
Since PDE4B was found abnormally expressed in diffuse large
B-cell lymphoma samples [35] the question arose what could be
the status of PDE4B expression in various CD4+ and other
lymphoid cancer cell lines. Therefore, a set of human CD4+
lymphoid tumor cell lines and an NK-like cell line, YT, were
examined by Western blotting that showed highly expressed
PDE4B protein present in these cells (Figure 6C). STAT5 signaling
pathway is relevant to several of these cell lines: human MT2 and
Hut102 and display hyperactive STAT5 pathway [37], while YT
and Kit225 cells undergo apoptosis when STAT5 is depleted
[11,38]. Intriguingly, PDE4B was found over-expressed in the
fraction of diffuse large B-cell lymphoma samples that were
refractory to chemotherapy [39]. It would be therefore interesting
to investigate cell fate if PDE4B could be effectively depleted and
whether death may result.
Taken together, it is plausible to postulate that overexpression of
PDE4B might be the result of abnormal genomic DNA binding of
STAT5 that could subsequently contribute to the tumorigenic
phenotype of these cell lines. Testing of this hypothesis requires
further investigation.
Conclusions
In conclusion, utilizing a systematic approach that combined
the determination of the IL-2 induced STAT5 cistrome and gene
expression analysis within a human leukemia cell model; and with
follow-up gene ontology as well as medium throughput transcript
expression validation in primary human PBMCs we have
identified 19 novel STAT5 target genes, some with functions
yet-to-be determined and some with relevance to immune cells.
We also validated a novel candidate target gene, PDE4B at the
protein level in PBMCs and found it over-expressed in CD4+
lymphoid tumor lines. These data also suggests that tumor cells of
lymphoid origin might have skewed genomic STAT5 binding sites
Determining the STAT5 Cistrome in Leukemia Cells
PLOS ONE | www.plosone.org 5 February 2013 | Volume 8 | Issue 2 | e57326
and hence target genes as compared to normal lymphoid cells (as
suggested by the comparison of our data with already existing data
in the literature by Liao and colleagues [16]); therefore, finding
specific targets to eradicate them might require genome-wide
mapping of larger sets of primary tumor samples of the same
origin. Whether lymphoid cells with an overactive STAT5
pathway might be sensitive to PDE4B inhibitors and a mechanism
to control certain tumors will be the subject of future studies.
Materials and Methods
Cell Culture and Treatment
The human lymphoma cell line YT [40], CD4+ human T-cell
lines Hut-102 [41] and MT-2 [42], thymus-derived CD4+ T-
lymphocyte cell line Molt-3 [43], CD4+ T-cell line H9 [44] and
human CD4+ IL-2 dependent leukemia cell line Kit225 [45]
(kindly provided by Dr. J. Johnston, Queens University, UK) were
cultured as described [4,38]. IL-2 was obtained from the NCI
Preclinical Repository. Human peripheral blood mononuclear
cells (PBMC) were isolated, activated with PHA and maintained as
Figure 3. Genome-wide visualization of chip-on-ChIP identified (magenta), Gene Expression Analysis (GEA) and chip-on-ChIP
overlap (green) and select (blue) putative STAT5 binding sites chosen for validation. Visualization of the results obtained from the
genome-wide identification of IL-2 induced genes and STAT5 binding sites (as described in Fig. 1) using the IGV.
doi:10.1371/journal.pone.0057326.g003
Figure 4. Genomic location of IL-2 regulated STAT5 binding sites. (A) Shown are known STAT5 target genes including SOCS2, SOCS3, CISH
and those also identified by chip-on-ChIP (IL2RA, BCL2, BCL6 and CDK6) and (B) 18 newly identified promoter located genes visualized by the IGV
using hg19.
doi:10.1371/journal.pone.0057326.g004
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described [46]. CD4+ or CD8+ T-cells were isolated by negative
selection using DynabeadsH UntouchedTM Human CD4 T Cells
(Cat. no. 113.46D) or Human CD8 T Cells (Cat. no. 113.48D)
kits, respectively.
Chromatin Immunoprecipitation
Chromatin immunoprecipitations were performed from ap-
proximately 56107 Kit225 cells as described [4] with anti-
STAT5A/B antibodies (mixing sc-1081 and sc-835 (C-terminal
STAT5A and STAT5B antibodies, respectively)) or normal rabbit
serum (IgG control) for 3 h at 4uC. To confirm that the assays
were successful, PCR amplification of the known STAT5 binding
site located 59 to the human IL2RA gene within the Positive
Regulatory Region III [23] (Forward: 59-ACG TCT AGA AAG
AAA GTG GTC-39 Reverse: 59- CTG TCC CTG GAT GAA
CCT AGT-39) was performed using quantitative real time PCR.
[4] Values of transcripts in unknown samples were obtained by
interpolating Ct (PCR cycles to threshold) values on a standard
curve. Standard curves were prepared from known amounts of
purified, PCR-amplified DNA. ChIP qPCR primer assays for
PDE4B ChIP validation were ordered from SABiosciences,
a Qiagen company (Cat# GPH900044(2)01A), by providing
chromosomal positions for the 250 bp surrounding the putative
GAS site (chr1:66569949–66570198, hg18). PCR reactions were
carried out using 26 SYBR Green Mastermix from BioRad and
a BioRad iQ5 thermocycler in triplicates. Arbitrary units defined
as ‘‘DNA binding, (Db)’’ was obtained by 2ˆ(2averageCt) and
standard deviation as SD < ln(2) * stdev(averageCt) * Db.
Random Amplification of Chromatin
Immunoprecipitated DNA
To generate libraries from ChIP-ed DNA, random amplifica-
tion was carried out as described at http://research.stowers-
institute.org/gertonlab/protocols/RandomPCRamplification.pdf
by the DeRisi lab at the UC San Francisco. Briefly, ChIP-ed DNA
samples were amplified with a modified version of a random PCR
protocol [47]. DNA was annealed to primer A (59-
GTTTCCCAGTAGGTCTCNNNNNNNN), and second-strand
DNA synthesis was carried out with Sequenase (US Biochemical).
This material was then used as the template for 35 cycles of PCR
with Primer B (59-GTTTCCCAGTAGGTCTC) using the
following profile: 30 s at 94uC, 30 s at 40uC, 30 s at 50uC, 60 s
at 72uC and a dNTP mix containing dUTP. The products were
purified with QIAGEN PCR purification kit, quantified and run
on a 1% agarose gel to check for fragment size, then tested for
enrichment of the Positive Regulatory Region III as described
above.
In Silico Analysis
Chip-on-ChIP results were analyzed with MAT (Model-based
Analysis of Tiling array, [24] http://liulab.dfci.harvard.edu/
MAT/) by the Liu Lab in the Department of Biostatistics and
Computational Biology at the Dana-Farber Cancer Institute,
Harvard School of Public Health. Proximal gene mapping of the
genomic sequences up to 300 kb was performed using the Cis-
Regulatory Element Annotation System (CEAS http://liulab.dfci.
harvard.edu/CEAS/). The results were visualized by the IGV.
The conversion of genome coordinates and genome annotation
files of different versions of the human genome assemblies was
performed using UCSC Genome Liftover tool at http://genome.
ucsc.edu/cgi-bin/hgLiftOver.
RNA Isolation and cDNA Synthesis
Total RNA was isolated using the RNeasy kit (QIAGEN).
cDNA was synthesized with BioRad’s iScript cDNA Synthesis Kit
according to the manufacturer’s instructions.
Microarray Analysis
Gene Expression Analysis using Affymetrix Human Genome
U133 Plus 2.0 microarrays were carried out at the Microarray
Core Facility, Baylor College of Medicine, Houston, TX.
Statistical analysis was performed using GeneSpring GX at the
University of Debrecen. Affymetrix GeneChip Human Promoter
1.0R arrays interrogate regions proximal to transcription start sites
and contain probes for approximately 59 percent of CpG islands.
These arrays contain 4.6 million probes tiled through over 25,500
human promoter regions at an average resolution of 35 bp. Each
promoter region covers approximately 7.5 kb upstream through
Table 1. Validation of STAT5-dependent, IL-2-mediated gene
expression changes.
Fold Response (to
ctrl)
p-value (to ctrl )
,0,05
GL Symbol 3 h 6 h 3 h 6 h
1 En AHR 4.53 4.41 0.0722 0.0177
2 Ex BCL2 2.75 2.07 0.0500 0.1099 *
3 Pp BCL6 23.76 24.19 0.0001 0.0207 *
4 Pp CD69 2.29 2.28 0.0500 0.0500
5 ID CDK6 3.61 3.34 0.0091 0.0089 *
6 En CDKN2C 21.80 21.96 0.0674 0.0312
7 CISH 28.73 21.18 0.0001 0.0002 *
8 Pp EMP1 3.06 1.69 0.0496 0.3392
9 Pp EPHA4 28.67 214.95 0.0051 0.0002
10 FOXP3 4.04 3.03 0.0035 0.0090 *
11 Pp IDI1 2.09 2.01 0.0209 0.0379
12 IFNG 15.19 11.19 0.0086 0.0403 *
13 Pp IL2RA 7.44 6.22 0.0010 0.0015 *
14 Pp LCP2 1.79 1.66 0.0384 0.0078
15 ID LRMP 23.12 225.91 0.0044 0.2041
16 ID MKI67IP 1.60 1.73 0.0153 0.0064
17 Ex MMD 2.43 2.14 0.0092 0.0512
18 Pp NETO2 2.87 2.58 0.0369 0.0210
19 Pp PDE4B 2.19 1.96 0.0042 0.0058
20 En RAFTLIN 1.01 21.36 0.9631 0.0229
21 Ex SLC2A3 1.75 1.63 0.0075 0.0215
22 Pp STIP1 3.25 2.55 0.0010 0.0309
23 En STK17B 1.49 1.44 0.0994 0.0185
24 Pp UBE2W 2.35 2.44 0.0500 0.0639
25 En UGP2 1.57 1.55 0.1079 0.0446
26 En WDR3 1.73 1.56 0.1103 0.0416
Transcript level changes of 57 intersect genes were measured using qRT2PCR
arrays in PHA activated, quiescent and IL-2 stimulated (3 and 6 h) PBMCs (72 h
activated, 48 h quiescent, from 3 independent donors). Fold response and the
p-value to the un-stimulated control samples are shown. Bold letters indicate
significantly up-regulated, while italic letters represent significantly down-
regulated genes. Stars specify known target genes. Genomic locations are
marked as follows: Pp, Proximal Promoter; ID, Immediate Downstream; En,
Enhancer; E, Exon. Unlabeled boxes contain genes that were identified by GEA
but not chip-on-ChIP.
doi:10.1371/journal.pone.0057326.t001
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2.45 kb downstream of 59 transcription start sites. For over 1,300
cancer-associated genes, coverage of promoter regions was
expanded to include additional genomic content. Fragmentation
and microarray hybridization to Affymetrix GeneChip Human
Promoter 1.0R arrays were carried out according to the
manufacturer’s instructions by the Genomics Core Facility at the
European Molecular Biology Laboratory in Heidelberg, Germany.
The data is available at the Gene Expression Omnibus Database
(https://www.ncbi.nlm.nih.gov/projects/geo/Accession:
GSE40624).
Gene Ontology Analysis
To identify overrepresented GO categories within the IL-2
regulated genes, the Ingenuity Pathway Analysis software was
used.
Figure 5. STAT5 binds PDE4B in an IL-2 inducible manner in hPBMC. ChIP assays performed with STAT5 antibodies or control sera (IgG) were
carried out in quiescent (2) or IL-2 stimulated (30 min, +) hPBMCs isolated from three independent donors to measure the enrichment of the PDE4B
putative STAT5 regulated region (A) or the IL2RA enhancer PRR III (B) identified by chip-on-ChIP. Inputs represent 1% of chromatin used in ChIP
assays and error bars represent standard deviations. * represents statistically significant differences (p,0.05).
doi:10.1371/journal.pone.0057326.g005
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Cell lysis and Western Blotting
Cell lysis and Western blots were performed as previously
described [38] with antibodies to PDE4B (Abnova, Catalog #:
PAB6965) and ß-actin (Sigma-Aldrich). The antibodies were used
at a dilution recommended by the manufacturer. Densitometry
analysis was performed using the Un-Scan-It version 6.1 software
by Silk Scientific, Inc.
RT2 Profiler PCR Arrays
To determine the expression profile of genes regulated by IL-2,
SA Biosciences’ Human PCR Arrays were used. Quantification
based on real-time monitoring of amplification was determined
using a BioRad iQ5 thermocycler and 26 SYBR Green
Mastermix (SA Biosciences, a Qiagen company). Treatments were
performed in triplicates and data was analyzed using the DDCt
method.
Statistical Analysis
Normalized t-tests were performed using SigmaStat 3.1.
Supporting Information
Figure S1 Experimental design of a genome-wide
approach to identify STAT5 specific IL-2-induced genes.
Kit225 IL-2-dependent human leukemia cells were stimulated
with IL-2, cross-linked with formaldehyde then chromatin
immunoprecipitated with antibodies to STAT5A/B. Eluted
DNA was amplified then probed against human Affymetrix
Promoter arrays and data analyzed to generate a pool of genomic
locations with putative and known STAT5 binding sites. (Flow
chart on the left.) Quiescent Kit225 cells were left un-stimulated or
were stimulated with IL-2 for 3 hours then Gene Expression
Analysis (GEA) performed to detect IL-2 responsive genes. (Flow
chart on the right.) The data pools then were aligned using UCSC
Genome Browser then gene expression changes of select genes
from the overlapping hits were validated using SABiosciences
qRT2PCR arrays in PHA activated quiescent PBMCs isolated
from three independent donors.
(TIF)
Figure 6. IL-2 stimulation induces PDE4B in activated human PBMCs (A) and CD8+ but not CD4+ T-cells (B). Normal human PBMCs from
three independent donors (shown are 2 representative results) were left un-activated (N, naı¨ve) or were activated with PHA (A, Q, +) then made
quiescent after 72 hrs PHA activation by CO2 stripping as described in the Materials and Methods section (Q), then stimulated with IL-2 for 3 h (+).
Cells were harvested and then Western blotted with antibodies to PDE4B or ß-actin as indicated to the right. Molecular weight markers are shown to
the left. In the lower panel immediately after PBMC isolation CD4+ (lanes f-i) or CD8+ (lanes b-e) cells were negatively selected as described in the
Materials and Methods section using magnetic beads, and then activated with PHA, made quiescent, stimulated with IL-2 and Western blotted for
PDE4B and ß-actin as described above. YT cells served as positive controls for PDE4B expression. (C) PDE4B is expressed in CD4+ lymphoid
tumor cell lines. Kit225, H9, Molt3, MT2, Hut102 CD4+ and YT NK-like lymphoid cell lines were lysed and equal amounts of protein Western blotted
for PDE4B and ß-actin as described for Figure 6A. Representative data from two independent experiments is presented.
doi:10.1371/journal.pone.0057326.g006
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Figure S2 Pathway analysis predicted activation of
STAT5A and STAT5B transcription factors by IL-2. Based
on the appearance of their target genes in the IL-2 regulated gene
list (GEA analysis, 469 genes changed, 340 up- and 129 genes
down-regulated) Ingenuity Pathway Analysis created the network
of genes visualized by their subcellular localization. Red indicates
up- and green shows down-regulated genes.
(TIF)
Figure S3 IL-2 regulated top networks based on In-
genuity Pathway Analysis of GEA results. Cellular De-
velopment & Cell Cycle, Hematological System Development &
Function, Reproductive System Development & Function as well
as Cellular Movement, Growth & Proliferation were found
significantly overrepresented within the GEA generated gene list.
(TIF)
Figure S4 Densitometry analysis of PDE4B protein
expression in hPBMC. Arbitrary units were generated by the
Un-Scan-It v6.1 software counting total pixels of the bands in the
Western blot images in Fig6A for both ß-actin and PDE4B in both
donors, and then the ratio of PDE4B/ß-actin was generated and
compared to the naı¨ve (N) samples. Error bars represent standard
deviations.
(TIF)
Table S1 Select putative IL-2 sensitive STAT5 target
genes. Table shows the 57 intersect genes chosen for validation
with their genomic locations in relation to the corresponding
regulated gene as well as their RefSeq IDs. Genomic locations are
marked as follows: Pp, Proximal Promoter; ID, Immediate
Downstream; En, Enhancer; E, Exon.
(XLSX)
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